Fee-For-Service (FFS) contracts, first introduced in 2004, dramatically changed the way the pharmaceutical distribution supply chains are designed, managed, and operated. Investment buying (IB), forward buying in anticipation of drug price increases, used to be the way the distributors made most of their profits! FFS contracts limit the amount of inventory distributors can carry at any time (by imposing an inventory cap) and require inventory information sharing from the distributors to the manufacturers while compensating the distributors with a per-unit fee. In spite of its widespread popularity, FFS model has never been rigorously analyzed and its effectiveness carefully tabulated. In this paper, we formulate the multi-period stochastic inventory problems faced by the manufacturer and the distributor under the FFS and IB models, derive their optimal policies and develop procedures to compute the policy parameters. We show that FFS contracts can improve the total supply chain profit -the manufacturer and distributor are now able to share a larger pie. Thus, there exists a range of the per-unit fees that leads to pareto-improvement. Simulation results show that such improvement is about 1.7% on average and as much as 5.5% and the improvement increases as the inventory cap decreases. Determining the pareto-improving per-unit fees is a source of contention in FFS contract negotiation and we propose a simple, yet effective, heuristic for computing them. Further, supply chain transparency facilitated by the FFS contracts can significantly reduce the manufacturers supply-demand mismatch costs (by about 3.63% on average and as much as 13.01%) and we show that the manufacturer should take advantage of this transparency especially when the inventory cap and drug price increase are high and demand variance is low. We believe that these results have the potential to improve the efficiency of pharmaceutical distribution supply chains, thus reducing the healthcare costs that are such a big burden on the U.S. economy.
Motivation And Introduction
American pharmaceutical industry, with cumulative revenues of more than 315 billion dollars in 2007, is the largest in the world. In the same year, US government spent $7, 285 per person on healthcare and $878 of that was spent on drugs. The pharmaceutical industry is one of the most profitable businesses in the U.S. and Bureau of Labor Statistics estimates that pharmaceutical and medicine manufacturing alone provided 289,800 jobs in 2008. The pharmaceutical industry plays a vital role in the larger U.S. economy and it is imperative that any and all possible efforts are made to ensure smooth and efficient operation of that industry.
Despite the importance of the pharmaceutical industry, the operations management community has thus far conducted very little research that captures the uniqueness of pharmaceutical supply chains. This is a significant cause for concern given that this industry has recently undergone dramatic changes and faces great challenges over the next few decades, forcing itself to take a deeper look at (and resolve) its supply chain issues. Recently, Schwarz and Zhao (2010) provided an overview of the industry based on their research of the industry data and interviews of industry executives. Following up on their observations, we conduct rigorous analysis of two distribution business models (Investment Buying and Fee-For-Service) that the pharmaceutical industry has used (details are provided later) and we particularly address the industry challenges of how to best take advantage of the FFS model is widely used.
The pharmaceutical supply chain, overly simplified, is composed of the manufacturers, the distributors, and the providers or chain retailers who sell to the end users of the pharmaceutical products. While the distributors are highly concentrated (the top three distributors take up more than 90% of the market), the brand-name manufacturing is more diverse in nature (in the United States, the 10 largest pharmaceutical corporations accounted for about 60% of sales in 2004).
Compared to other consumer product supply chains, pharmaceutical supply chains possess the following unique features:
1. In most consumer supply chains, distributors earn their margin by effectively managing both their upstream and downstream partners. In the pharmaceutical industry, the majority of the distributor margin comes from upstream because: (i) large retail pharmaceutical chains, which dispense the majority of pharmaceuticals, have significant buying power; and (ii) thirdparty payers such as Medicare, Medicaid, and insurance companies impose significant cost pressure on the distributors (Schwarz and Zhao 2010) .
2. Branded drug price continues to increase each year, attracting lots of attention (from the public, the media, and the government) for the pharmaceutical industry. Figure 1 shows the rate of drug price increases compared to inflation rates from 2002 to 2008. For many manufacturers, such price increases are rather predictable. For example, one big brand manufacturer always increases its drug prices on the first business day of each year. Some other manufacturers inform or signal their distributors in advance about price increases of particular drugs.
These predictable price increases have profound impact on the business strategies of the man-ufacturer and the distributor in the industry. In fact, before 2004, drug price increases had been distributors' major revenue source as they buy large stock in speculation of future price increases.
This business model is called the Investment Buying (IB) Model. Such practices have led to many disadvantages:
1. High and non-transparent inventory level at the distributors as they try to hide from the manufacturers how much inventory they have in order to buy how much ever they want. This behavior is further exacerbated by the liberal returns policy in this industry.
2. Big fluctuations in the order quantities from the distributors, making production and inventory planning difficult for the manufacturers; 3. Loss of revenue for the manufacturers due to distributors' investment buying.
4. Distributors have less stable revenue sources as they have to rely on speculation instead of services provided to the manufacturers to make profits. Despite the above mentioned issues, investment buying remained the principal business model for the pharmaceutical distributors until 2004, when an industry-wide switch from IB to Fee-for-Service (FFS) took place. Indeed, this change was fascinating in its scope and speed (all top-3 distributors changed to FFS model with most of their suppliers within one to two years (Fein 2007) ). There are many reasons for this switch, including the issues mentioned above, but most importantly, an SEC (Security and Exchange Commission) investigation of a big pharmaceutical manufacturer (Bristol Myers Squib, BMS) for channel stuffing facilitated by the practice of investment buying.
Under the Fee-For-Service (FFS) model, the distributors draw their revenue mainly from the fees charged to the manufacturer for services provided to them. The services provided include maintaining an inventory level within specified ranges and provide transparency by sharing inventory level and other information (e.g., demand). Specifically, under FFS model, the Inventory Management Agreements (IMA) between the manufacturer and the distributor specifically control the inventory level at the distributors. Distributor's inventory level is required to be high enough to maintain a mutually agreed upon service level to the downstream customers and low enough to control investment buying. It is important to point out that under FFS/IMA, distributors still increase their inventory levels before price increase (a rational action for a decentralized distributor), however, the amount of investment buying is controlled by the maximum level of inventory that the distributor is allowed to carry at any time as specified in the FFS/IMA contracts. Such contracts are easily verifiable due to the aforementioned information sharing. Thus, when appropriately implemented, a FFS/IMA contract reduces investment buying by the distributor, reduces the variability in the demands that the manufacturer faces, and improves transparency throughout the supply chain.
Industry data has shown (Schwarz and Zhao (2010) ) that the impact of FFS/IMA on pharmaceutical distributors has been profound as they are forced to be more efficient in achieving the same service level with significantly lower inventory. However, FFS/IMA and particularly information-sharing enabled by FFS/IMA have had little impact on pharmaceutical manufacturers' own inventory-management practices. According to the interviews conducted by Schwarz and Zhao (2010) , part of the reason is the lack of decision support mechanism on how to use the information now provided to the manufacturers under FFS. Indeed, although the research on the value of information and how to incorporate information into manufacturers' decision making is extensive (e.g., Gavirneni, et al. 1997 and Chen 2003) , little is done to tackle the unique challenges in the pharmaceutical industry. At the same time, the pharmaceutical industry is facing another difficult question -the design of the FFS/IMA contract. Since its inception in 2004, distributors and man-ufacturers have been trying their own ways to set contract parameters because there have been no studies providing them any guidance in the important contract design problem. Furthermore, the question remains as to who actually benefits from FFS contracts. Is it (i) the distributors because of the fees they receive from the manufacturers, (ii) the manufacturers because of the reduced investment buying by the distributors, or (iii) the consumer because of reduced costs in the supply chain. The answer to this question is not so obvious. Our research shows that the supply chain is indeed better off from this switch. Further, if the fees are determined appropriately, both the manufacturer and the distributor can be better off from switching from an IB model to an FFS model. Thus, it is not a stretch of imagination to say that the pharmaceutical industry, by their implementation of the FFS contract, has found a true win-win situation.
Specifically speaking, the purpose of this research is to (i) characterize the manufacturer's and the distributor's optimal decisions under FFS; (ii) provide solutions as to how the industry players should operate under the FFS model; (iii) investigate how each FFS parameter affects each player's and supply chain's profit; and (iv) by comparing each player's performance under FFS and IB models, provide guidance regarding FFS contract design, and in particular how to set the FFS contract parameters such that each player can be better off under FFS than under IB model. An extensive simulation study verified the analytical results and provides additional managerial insights useful for this industry.
Before we detail the supply chain setup, the analytical results, and the computational results, we would like to briefly describe our main findings. We formulated the stochastic inventory control problems faced by the manufacturer and the distributor, established that the produce-up-to and order-up-to policies are optimal for them, respectively, and developed procedures to compute the FFS parameters. A comprehensive simulation study demonstrated that FFS contracts improve the total supply chain profit by about 1.7% on average and by as much as 5.5%. Unfortunately, these profit gains are not universal in the sense that the manufacturer profit increases while the distributor profit is reduced. Therefore, it is necessary for the manufacturer to share some of the gains with the distributor and the FFS fees are an ideal mechanism for this purpose. We are able to compute the fee range that results in pareto-improvement for both the players. We further develop simple heuristics for computing these levels and demonstrate their effectiveness.
The rest of the paper is organized as follows. In §2, we briefly review the literature. In §2, we formally introduce the supply chain model set up. In §4 and §5, we characterize the manufacturer's and distributor's optimal policy under FFS and IB models, respectively. In §6, we investigate the FFS contract design problem through simulation study. We also derive an easy-to-implement heuristic and demonstrate the effectiveness of this heuristic through numerical study. In §7, we conclude the paper with a summary of the managerial insights.
Literature Review
Relatively little has been published in the supply chain and operations management literature that is directly on pharmaceutical supply chains. Burns et al. (2002) is the most frequently cited general reference. Schwarz (2010) describes the flows of products, dollars, and information in the supply chains for medical and surgical supplies, pharmaceuticals, and orthotic devices. Most other available resources are website postings and reviews from industry experts, consulting companies, and industry reports. Yost (2005) and Fein (2005 Fein ( , 2007 Recently, Schwarz and Zhao (2010) conducted some empirical research focused on the pharmaceutical industry. They provided an overview of the industry, its current status, and the challenges it faces, from the operations perspective. Based on their analysis of the industry data and interviews of industry executives, they also examined the impact of FFS/IMA contracts on the pharmaceutical distributors and manufacturers. They concluded with a discussion of many current issues that are worth the attention of the supply chain/operations management researchers.
Very limited research addresses the pharmaceutical supply chain using analytical models. Recently, Martino et al. (2010) examines the different distribution models for the pharmaceutical supply chain using a mathematical model. Specifically, they compare IB, FFS, and direct-to-pharmacy model for the manufacturer by considering cases where the aggregated demand is deterministic and determine the profit maximizing production-inventory strategy in a multi-period setting for the manufacturer and wholesaler under each contractual agreement. They do not consider fee designs or value of information (in fact, the value of information cannot be studied in this case due to the demand being deterministic).
To our knowledge, our paper is the first to analytically study the supply chain, from a multistage stochastic inventory perspective, under the IB and FFS business models. By solving the optimal inventory and production policy under each model, we show how players change their behavior under different business models and how to best design FFS/IMA contracts to ensure pareto-improvement.
In addition to the limited research particularly targeted at pharmaceutical industry as discussed above, the research presented in this paper is related to a few areas in the operations area, including production and inventory control, production planning with information sharing, and supply chain management. In the following, we briefly review related literature in these areas.
First, our paper is related to the literature that studies production and inventory decisions in serial supply chains. Graves (1999) reviews production planning and inventory control models for centralized systems with predictable demand. When it comes to multi-stage supply chains with stochastic demands, Anupindi and Akella (1993) and Glasserman and Tayur (1995) were the early papers. Since then, there has been a plethora of research on these systems and most of it has been captured in books compiled by Tayur et al. (1999) and de Kok and Graves (2003) .
In modeling the FFS model, one important aspect is to incorporate the distributor's on-hand inventory information into the pharmaceutical manufacturers' production and inventory decisions and analyze the value of such information. A great deal of literature is available (see Chen (2003)) to demonstrate the value of downstream information to upstream suppliers. In particular, this literature shows that with more information about the downstream inventory or demand, manufacturers can improve production planning, better matching their stock levels with the demand, and hence reduce total costs. is the work that is most closely related to ours.
It compares a traditional model (in which downstream orders are the only information available to a manufacturer) with two models, one in which the manufacturer is informed of the downstream replenishment policy and its parameters and another in which the manufacturer is also informed of the downstream on-hand inventory information. Their numerical study shows significant savings (as large as 35%) for the manufacturer due to the modification of his production and inventory policy. Lee et al. (2000) , Cachon and Fisher (2000) , Aviv and Federgruen (1998) , and Simchi-Levi and Zhao (2004) report similar results. For a comprehensive literature review on value of information sharing, see Chen (2003) . None of the studies described above, however, incorporates the unique characteristics of the pharmaceutical supply chain. Price increase, which creates the non-stationary ordering process of the distributor to the manufacturer, is one such characteristic of brand-name drugs. As Lee et al. (1997) show, price uncertainty is one cause of the bullwhip effect. Although the FFS/IMA business model limits investment buying, distributors still take advantage of price increases within the boundaries of IMA contracts. Therefore, incorporating the impact of price increases is an important aspect when developing models for pharmaceutical decision making. Gavirneni and Morton (1999) study a retailer's inventory speculation behavior in case of price increase. In contrast, we study a three-level supply chain and show how price increase will change the behavior of the players at various levels in the supply chain.
There has been extensive literature on supply chain contracts in decentralized systems, e.g., wholesale price contracts, revenue sharing contracts, etc. and variations of these contracts. See Cachon (2003) for more detailed review. Most of these contracts are studied under the single-period setting and do not consider the price increase effect which is the key for the pharmaceutical industry.
The FFS contract is the pharmaceutical industry's particular way of limiting investment buying and compensating the distributors. It is essentially a profit/revenue sharing contract between the manufacturer and the distributors.
Investment buying and price fluctuation have been discussed in the operations literature mainly as a cause of demand information distortion, i.e., bullwhip effect (Lee, et al. 1997) . Much research discusses various ways to mitigate the bullwhip effect. These include demand information sharing (e.g., , vendor managed inventory (VMI) (e.g., Aviv and Federgruen 1998) , and collaborative planning, forecasting, and replenishment (CPFR) (e.g., Waller, et al. 1999 , Aviv 2001 ). In the pharmaceutical industry, price increase causes investment buying which brings many disadvantages. Directly limiting investment buying using contracts through inventory caps and information sharing are used to reduce the negative impact of investment buying, which are also the main targets of analysis in this paper.
Supply Chain Setup
Consider a three-level pharmaceutical supply chain, where the brand-name manufacturer (she) supplies the distributor (he) who sells to a retailer (representing a provider or a chain retailer) over an N -period finite horizon. The downstream retailer faces stochastic demand following i.i.d. distribution for each period k with a cdf Φ() and pdf φ(), which we assume to be known to the manufacturer and the distributor. The manufacturer produces to stock with lead time of one period for regular production. She fills the demand from her stock and any unmet demand is satisfied immediately using overtime or any other possible means reflected in a penalty cost, p.
Although this assumption is mainly for simplification of the analytical model, it is not far from reality since "typically the manufacturer tries all possible means (using overtime or dispatching stocks from different inventory depots) to avoid stockouts", according to a manager in one of the top-3 distributors. The distributor fills demand from his stock and any unsatisfied demand at the distributor is backordered with a shortage cost, p d . We assume no lead time for distributor's orders.
The distributor's lead times may be added which will complicate the model with little additional insights. In each period, the manufacturer determines how much to produce (for the next period) and the distributor determines how much to order.
We consider and compare the FFS model with the IB model over a finite horizon, corresponding to an average length of time within which there is one price increase. For example, if the price of a branded drug is increased every year, the finite horizon is set to be one year, with the price increase occurring in the middle of the horizon. Formally, we assume there is a price increase, δ, in the middle of the horizon at the beginning of period n (n ∼ N/2). Notice that, in reality, there may be more than one price increase during the drug's patented years. However, as we will show, after one price increase, each individual party as well as the supply chain settle down to a new steady state. As long as the two price increases are far enough so that their impacts do not interact (which is the case in reality), we can decompose the different price increases and focus, as we do here, on the impact of one price increase on the performance of individual parties and the supply chain. We assume all unsold inventory can be returned to the manufacturer with full refunds at the end of the finite horizon (this is consistent with the very liberal returns policy in this industry)
and hence we will see stationary policy over the finite horizon. We also assume the manufacturer's and distributor's unit holding costs and unit shortage penalty costs do not change after the price increase.
To summarize, in every period, the sequence of events is as follows: (a) the manufacturer receives the units produced in the previous period; (b) the distributor places an order if needed for that period; (c) if the manufacturer does not have enough inventory to fulfill the demand, she gets the product immediately from overtime (or expediting from other depots) at a higher cost; (d) the manufacturer ships the product to the distributor; (e) the manufacturer decides how much to produce (which will be available for next period); (f) distributor's demand realizes and he satisfies the demands as much as possible from his inventory. Unsatisfied demand at the distributor is backlogged; (g) inventory-related costs (holding costs for the manufacturer and distributor, backorder costs for the distributor and shortage penalty cost for the manufacturer) are tabulated.
Model FFS: Under the FFS model, the manufacturer imposes an upper limit on how much inventory a distributor can hold (inventory position),ȳ, referred to as the distributor's inventory cap. Such an inventory cap effectively controls the amount of investment buying. As a result, the distributor charges a fee (u) from the manufacturer for each unit the manufacturer distributes through him, as the "compensation" for his loss of revenue for investment buying, or in another term, for his service. The distributor also shares with the manufacturer how much on-hand inventory he has at the beginning of each period. Because of this information, the manufacturer is able to calculate the total customer demand seen by the distributor since he last places an order to the manufacturer (i.e., the investment buying period) and uses that to more accurately estimate the distributor's future orders after the price increase. As we will show, in the periods following the price increase, the manufacturer will have a state-dependent base-stock policy with the state defined as the total customer demand seen by the distributor since he last places an order to the manufacturer (i.e., the investment buying period).
Model IB: Under the IB model, there is no limit of how much the distributor can order and the manufacturer does not have information about distributor's on-hand inventory. Hence, the manufacturer can only estimate the distributor's demand by the number of periods since the investment buying period. As we will show, under IB, in the periods following the price increase, the manufacturer will again have a state-dependent policy, with the state defined as the number of periods since the manufacturer's last demand. It is easy to see that IB model is a special case of FFS model withȳ = ∞, u = 0, and no on-hand inventory information sharing.
Before we move on to detailed analysis, we first summarize notations used, some mentioned above, others not. 
Fee-for-Service Model
In this section, we analyze each player's optimal policy under FFS. As we mentioned before, under FFS model, there is an inventory cap (ȳ) as to how much inventory the distributor may hold in any period and distributor shares his on-hand information with the manufacturer. The distributor charges a fee, u, for each unit that the manufacturer sends to him.
Distributor's Optimal Policy
Due to backorders, distributor's expected revenue/sales is not affected by his inventory decisions.
Hence, his optimal ordering policy is obtained by minimizing his expected cost. Let V d k (x) represent distributor's expected optimal cost from period k to the end of the horizon, given he starts this period with an on-hand inventory of x. We have
Note that before the price increase, i.e., 1
As mentioned, we assume the distributor's terminal cost function as:
which means at the end of last period, the distributor can return all leftover units with full refund. Moreover, in FFS/IMA contracts, there is an end-customer fill-rate requirement from the manufacturer to the distributor, γ, corresponding to a minimum stock level, y = Φ −1 (γ) at the distributor. Due to the high penalty cost for not filling a demand immediately, we assume that all newsvendor quantities satisfy the minimum stock level, y. Following the standard backward induction, we obtain the distributor's optimal policy, summarized in the following theorem.
Theorem 1 Define y
The distributor's optimal policy is a non-stationary basestock policy with the base-stock level equal to min(ȳ, y d * k ), where y d * k = y * for any period other than n − 1 and y d * k = y d * n−1 for period n − 1 with y d * n−1 ≥ y * , ∀k = n − 1.
Theorem 1 shows that the distributor maintains his newsvendor base-stock level in all the periods except in the period right before price increase (period n−1) in which he will do investment buying as much as allowed by the inventory cap, i.e., y
Manufacturer's Optimal Policy
Because all distributor orders are satisfied from the manufacturer (either from her inventory or from overtime production), the manufacturer's sales is equal to distributor demand which is not related to her production and inventory decision. Hence, the manufacturer's production decision could also be solved to minimize her relevant expected cost. For tractability, we assume the manufacturer's terminal cost to be V N +1 (x) = −cx.
To capture the manufacturer's expected cost, we need to characterize her demand process.
Since the distributor has a stationary base-stock policy for periods 1
the manufacturer will see i.i.d. demand from the distributor with a pdf of φ() before period n − 1.
Because of investment buying in period n − 1 before price increase, there may be one or more period(s) starting from period n (price increase period) during which the manufacturer does not see demand. We refer to these periods as transitional periods, k = n, n + 1, .... After the distributor resumes ordering, he will have stationary base-stock levels (Theorem 1), hence, the manufacturer will again see i.i.d. demand following a pdf of φ(). Note that the length of the transitional periods is uncertain and the first positive demand seen by the manufacturer once the distributor resumes ordering also follows a different distribution depending on the number of transitional periods. Since the distributor shares on-hand inventory with the manufacturer, she can use this information to help estimate the distributor's demand process for k ≥ n.
Specifically, define the state of the manufacturer as follows: (1) Before the price increase (k ≤ n− 1), the manufacturer is in state 0 − ; after the distributor resumes his ordering, she is in state 0 + . (2) During the transitional periods, the manufacturer's state, i = 0, 1, ...,ȳ− y * − 1, represents the total downstream demand realized at the distributor since his investment buying in period n − 1. Now define p i , 0 ≤ i ≤ȳ − y * − 1 (i.e., p i is defined only for the transitional periods), as the probability that manufacturer sees a positive demand in state i, hence,
where D is the random demand seen by the distributor in one period. If the manufacturer sees a demand from the distributor in state i, the demand,
in this case, follows a distribution with a cdf of Θ i (η i ). It is easy to verify that p i ≤ p i+1 and
, for i <ȳ − y * − 1, i.e., the chance and quantity of distributor demand realization increase as time goes along after the price increase.
Let V i k (x) be the manufacturer's minimum expected cost 2 from period k to the end of the horizon when she is in state i at period k with a starting inventory of x. We have
where
The following theorem shows the optimal production and stocking policy for the manufacturer.
Theorem 2 Under the FFS model,
• A produce-up-to policy is optimal for the manufacturer. The policy is characterized by a series of produce-up-to levels, y i k , for period k in state i. Particularly, before the price increase, the produce-up-to levels are y 0 − k , k < n. After price increase (k ≥ n), the produce-up-to levels are uniquely defined by their state, referred to as y i , i = 0, 1, 2, · · ·,ȳ − y * − 1, 0 + .
• The optimal produce-up-to levels in the transitional periods have the following relationships:
The above theorem shows that because of price increase, the manufacturer's optimal stock level drops to a low level in the period of price increase (n), increasing during the transitional periods until the distributor resumes ordering, from which time it remains at the newsvendor quantity through the end of the horizon. The following corollary shows that asȳ increases, the manufacturer's optimal stock levels will decrease in the transitional periods and remain at the newsvendor quantity after the distributor resumes ordering.
does not include the manufacturer's fees to the distributor since they are only affected by the downstream demands, not by her production decisions.
Investment Buying Model
As mentioned above, the IB model is a special case of the FFS model with (1)ȳ = ∞, (2) u = 0, and (3) no sharing of distributor's on-hand inventory to the manufacturer. Therefore, the distributor's policy is the same as that under FFS withȳ = ∞ and u = 0.
As for the manufacturer's policy, since the distributor does not share his on-hand inventory information, during the transitional periods, she can only estimate distributor's demand based on how many periods have elapsed since the distributor's last order (investment buying in period n − 1). Hence, while the manufacturer is still in state 0 − before the price increase and in state 0 + after the distributor resumes ordering after the price increase (as defined in FFS model), during the transitional periods, state i is re-defined as the number of periods that have elapsed since the distributor's investment buying in period n − 1, 0 < i ≤ N − n + 1, i ∈ I + (positive integers).
During the transitional periods, still define p i , 0 < i ≤ N − n + 1, as the probability of manufacturer seeing the distributor resuming ordering in state i.
We also define the distributor's demand to the manufacturer (η i ), if realized in state i, follows a distribution with a cdf of Ψ i (η i ).
We assume that p i ≤ p i+1 and Ψ i (·) ≤ st Ψ i+1 (·), i.e., the chance and quantity of distributor demand realization increase as time goes along after the price increase. It is easy to show that both assumptions are true if the end-item retailer demand has an increasing failure rate (IFR) distribution (Normal, uniform, or Erlang distributions).
Let V i k (x) be the manufacturer's minimum expected cost from period k to the end of the horizon when she is in state i at period k with inventory x. We have V i k (x) = min y≥x {G i k (y) − cx}, where
With minor adjustment, the proofs for FFS model apply to IB model as well. Hence we briefly summarize the results: (1) The produce-up-to policy is the optimal policy for the manufacturer.
(2) The relationship of the optimal stocking levels in the transitional periods (Theorem 2) still hold. Further, the following theorem shows that as the amount of price increase increases, the manufacturer's optimal stock levels in the transitional periods decrease.
Theorem 3 If price increase amount δ 1 ≤ δ 2 , then y i (δ 1 ) ≥ y i (δ 2 ) for i ≥ 0, and y 0 + (δ 1 ) = y 0 + (δ 2 ).
Numerical Study
In this section, we conduct an extensive numerical study to determine how the FFS contract parameters affect supply chain performance. Further, we provide managerial guidelines on how these parameters should be set in order to achieve pareto-improvement. Specifically speaking, the objective of the computational study is to answer the following questions:
1. How does the inventory cap,ȳ, affect the manufacturer's, the distributor's, and the supply chain's profit? Asȳ decreases, we know that the distributor's profit decreases due to less investment buying. However, we do not know how the manufacturer's profit will change, because on the one hand, she enjoys less profit loss from investment buying, on the other hand, she will have less benefits from information sharing (the information is more useful to her under more investment buying). A priori, we also do not know what will happen to the total supply chain profit. We will use the computational study to better understand this behavior.
2. The per-unit fee (u) does not affect the supply chain profit; it only serves as means to divide the supply chain profit between the manufacturer and the distributor. What is the range of fees that will make the manufacturer and the distributor better off by shifting from IB to FFS? How are the fees affected by the various supply chain parameters?
3. Given the calculation of the fees depend on solution to multi-period stochastic models, are there any heuristics that managers can use to determine the pareto-improving fee values?
How effective are these heuristics?
4. What is the value of distributor's on-hand inventory information to the manufacturer? How do the various supply chain parameters affect this value?
To achieve our objective of quantifying and studying the value of information, we introduce
an "intermediate" model between FFS and IB. Referred to as FFS-NI, this model is the same as the FFS model except that the manufacturer does not use the on-hand information in her decision making. Under this model, the distributor makes the same decisions as under FFS, whereas the manufacturer makes her decisions without using the on-hand inventory information from the distributor. According to Schwarz and Zhao (2010) , pharmaceutical manufacturers have largely foregone the benefits of information shared with them by the distributor. Hence, studying the FFS-NI model and comparing to the FFS model will enable us to characterize the value of information that the manufacturer is foregoing in this process.
To answer these questions, we designed a comprehensive test bed of numerical experiments with the following parameter values. In the pharmaceutical industry, all prices (between manufacturer and the distributor and even also the selling prices to the retailers) are set in terms of a reference price, called Wholesale Average Cost (WAC), published to all players. It is interesting that WAC is never the true price between any two players, but nevertheless all the prices (For example, c d , r, u) are set as a percentage of WAC.
• Almost all distributors obtain 2% off WAC as prompt pay discount, which makes c d = 98%W AC.
• On average, distributors sell to the retailers at 2.7% off WAC, i.e., r = 97.3%W AC. Note that the distributors are selling at a price lower than their buying price. However, the distributors obtain positive margin because of the service fees.
• Manufacturer's production cost is typically very low, about 10% of WAC, i.e., c = 10%W AC.
• Holding cost at the distributor is more significant than at the manufacturer because of distributor's low margin and higher requirement for cash flow. Typically, annual holding cost at the distributor and at the manufacturer is 20% of WAC and 10% of c, i.e., h d = 20/24%W AC and h = 10/24%c (we look at a one-year horizon with 24 periods and h d and h are holding costs per period).
• Penalty costs are set to assure a 98% service level at both the distributor and the manufacturer using news-vendor quantity, i.e., p d = 49h d and p = 49h.
To summarize, we use the following parameters as discussed above: in the industry, we investigate the impact of a few other very important parameters that vary a lot in the industry and study their impact on the supply chain profit, the fees that should be used, and the value of information. These parameters are: WAC 3 , δ (the annual price increase percentage), the demand variance, and the inventory cap. Specifically, we set 5 levels of W AC = 200, 650, 1100, 1550, 2000 and 5 levels of δ = 5%, 7.5%, 10%, 12.5%, 15%. As for demand, we choose Erlang distribution, which may resemble normal distribution but does not have the concerns of negative demand and hence has more flexibility of the variance change. We choose 4 levels of variances by having Erlang with (µ, k) = (30, 1), (15, 2), (10, 3), (7.5, 4). These four sets of Erlang share the same average demand with decreasing variance level. For each of the above 100 sets of parameters, we also solve the problem under different levels of inventory caps. LetD be the expected value of the i.i.d random demand for one period. The inventory capȳ is chosen at its newsvendor amount (y * ) plus additional periods of average demand, i.e,ȳ is chosen at y * , y * +D, y * + 2D,..., and increase by an incremental ofD until it hits y d * n−1 , the distributor's stock level with full investment buying under IB. Beyond y d * n−1 ,ȳ does not limit investment buying any more. This usually includes at least 8 levels of inventory cap (depending on the price increase level). These settings are evaluated using a 24-period timeline designed to capture a one-year horizon with each period equivalent to half a month.
For each of 1337 cases described above, we use simulation with IPA (see Glasserman and Tayur (1995) for details) to solve for, under IB, FFS, and FFS-NI, the optimal production levels at the manufacturer, optimal stocking levels at the distributor, profits for each player and the supply chain, pareto-improving fee ranges, as well as the value of information measured by the percentage savings in the manufacturer's supply-demand mismatch (inventory holding and penalty) cost. In the following, we describe our findings on the supply chain and each player's profit, the paretoimproving fees, and the value of information. For each of these, we explore how their behavior is impacted by the inventory caps, price increase, and demand variance. Figure 2 shows how the manufacturer's, the distributor's, and the supply chain's average profit per period change with the inventory cap for a system with W AC = 200, δ = 10%, demand following Erlang (15.0, 2) distribution, and fee u = 2%W AC. Inventory caps are plotted in additional periods of demand. For example, an inventory cap of 0 and 2 in the figure corresponds toȳ = y * andȳ = y * + 2D, respectively. Observe that asȳ decreases, the distributor's profit decreases and the manufacturer's profit increases. This is along the lines of the arguments we presented earlier.
Impact of FFS on Supply Chain Performance
It is pleasant to see that asȳ decreases, supply chain profit increases. What this means is that a transition from IB to FFS will increase the supply chain efficiency, resulting in increased overall profit. Hence, a transition from IB to FFS is beneficial to the industry as a whole and the players are able to share a bigger pie. A summary analysis over all 1337 simulation cases reveals that the increase in system profit is 1.7% on average and is as large as 5.5%. For this specific example, a transition from IB to FFS has the potential to increase the system profit from $5, 982 to $6, 131
per period. This is a result of the manufacturer's profit increasing from $3076 to $3369 per period while the distributor's profit decreases from $2906 to $2762. Thus, if the manufacturer were willing to transfer about $144 per period to distributor (in addition to the 2% fee she currently pays), then the distributor should be ambivalent to the transition and the manufacturer will be able to keep the additional $149 resulting from this transition. Ideally some of these additional profits will be shared with the end-consumer as well (in the form of lower prices) and thus, as a result of the transition from IB to FFS, all the parties involved would be better off. The per-unit fee-for-service, u, used in the FFS contracts serves the aforementioned role of transferring profit from the supplier to the retailer. Since the benefit realized by the manufacturer is greater than the profit loss seen by the distributor, we can define upper and lower limits for the fees for pareto-improvement as follows.
Defineū as the value of the fee under FFS at which the manufacturer's profit is the same as that under the IB model and u as the value of the fee at which the distributor's profit is the same as that under the IB model. We haveū
and
where ∆π m (ȳ) is the manufacturer's expected profit gain when switching from IB model to a FFS model with an inventory cap ofȳ, and ∆π d (ȳ) is the distributor's expected profit loss when switching from IB model to a FFS model with an inventory cap ofȳ.
Clearly, since the increase of the manufacturer's profit is higher than the decrease of the distributor's profit (supply chain profit increases), u ≤ū. When the fee is set anywhere between these two values, both the manufacturer and the distributor are better off than they were in the IB model, thus achieving pareto-improvement. Within these pareto-improving ranges, the lower the fee is, the more profit is obtained by the manufacturer. In real-world contracts, where the fee lies depends on the negotiation power of the player. However, it is easy to see these two values of the fee are very useful in designing and managing FFS contracts effectively and our study is designed to estimate, using both optimal and heuristic procedures, these values and understand their behavior.
In closing this section, we would like to summarize our main observation in the form of guidelines to the various stakeholders in this industry:
Manufacturers: The manufacturers of brand-name drugs should be at the fore-front of this transition from IB to FFS as they have the most to gain from this transition. However, without appropriate incentives, the distributor in the supply chain may not follow and thus they should ensure that the distributor be appropriately compensated if they are to see a successful implementation of these contracts.
Distributors: While FFS provides more stable revenue than investment buying, they should realize that if the fees are not set up appropriately, they could be worse off than they used to be under IB model. Fortunately, with the implementation of FFS contracts, there is a larger pie to share, so they should work with the manufacturers to ensure that they get their fair share of this bigger pie.
Policymakers: Policymakers should acknowledge that the FFS contracts are better for the pharmaceutical industry and the economy as a whole and ensure that they enact policies that encourage the implementation of these contracts. They should also realize that some of the improved efficiencies or increased profits should potentially be shared with the end-consumers and they should urge the manufacturers and distributors to do so.
End-consumers: End-consumers are the ones that eventually bear the burden of the supply chain cost and they should realize that their burden is smaller under the FFS contract. In addition, they should demand a share of the increased profits.
Behavior of the Pareto-Improving Fee Levels
We compute the pareto-improving fees for all cases and investigate how different parameters impact the fee ranges. As is the industry norm, all fees are reported as percentages of WAC. Figure 3a shows the average pareto-improving fee ranges over all cases under different inventory caps,ȳ.
Notice that asȳ increases, the fees, both u andū, decrease. The manufacturer's breakeven fee,ū, decreases from 5.3% to 1.2% while the distributor's breakeven fee, u, decreases from 2.7% to 0.2%.
The reasons behind this behavior are as follows. Asȳ increases, the manufacturer's profit decreases thus urging her to provide a smaller fee. On the other hand, asȳ increases, the distributor's profit increases from more investment buying and thus he requires a smaller fee to break even. The magnitude of the fee interval (i.e.ū − u) also decreases asȳ increases because the improvement of the supply chain profit decreases asȳ increases (Figure 2 ). Figure 3b shows the average pareto-improving fee ranges (over all the instances with that value of δ) under different annual price increase rate, δ. It can be seen that as δ increases, the paretoimproving fees (both u andū) increase and the magnitude of the fee interval also increases. When the δ was set at 5%, the fee range was from 0.2% to 0.6% and when the δ was set at 15%, the fee range was from 1.8% to 4.2%. This is because a higher value of δ means more profit from investment buying and hence the manufacturer needs to pay more under FFS to compensate for the profit loss the distributor sees from the restriction on investment buying. and by the use of information shared from the distributor. As the demand variance increases, the value of information decreases (discussed in the next subsection) resulting in a slight decrease in the fees that she is willing to pay to the distributor.
In addition to these observations, our numerical study also confirms that fees, as a percentage of WAC, are not affected by WAC since all parameters and fees are represented as percentages of WAC.
In closing this section, we would like to summarize our findings in the form of the following managerial guidelines:
1. When the inventory cap is small, the manufacturers should offer a larger per-unit service fee and the distributors should expect a larger fee. Both the distributor and the manufacturer have a little more leeway in deciding the pareto-improving fees whenȳ is small whereas when
y is large, they should be very careful in determining the fees because there is increased possibility that they could arrive at a value that is not pareto-improving.
2. When the price increase (as a percentage of WAC) is small (high), the manufacturers should offer a lower (higher) fee and the distributors should expect a smaller (larger) per-unit fee.
The determination of the pareto-improving per-unit fees should be done more carefully at lower values of δ as the magnitude of the effective interval is smaller.
3. The level of the fees that a distributor expects should not be impacted by the variance of the end-customer demand whereas the manufacturer should offer a smaller fee when the end-consumer demand has a higher variance.
Value of Information
Here, we study the manufacturer's performance under FFS and FFS-NI, whose difference reflects the value of the on-hand inventory information shared by the distributor with the manufacturer.
We measure value of information as the percentage savings of the manufacturer's supply-demand mismatch (inventory holding and penalty) cost when using the distributor's on-hand inventory information. We observed that, over all the instances in our study, the average value of information is 3.63% and this value can be as high as 13.01%. This is because, asȳ increases, the distributor will have more investment buying quantity leading to longer periods (following investment buying) in which the distributor does not place an order (longer transitional periods). It is during these periods that the information shared from the distributor to the manufacturer is useful and thus the average value of information increases withȳ. Figure 5b shows that as price increase (δ) increases, the value of information will first increase and then flatten out (after δ reaches 10%). This is because, as δ increases, the investment buying quantity and hence the number of transitional periods increases. Thus the value of information increases. However, there is a limit as to how much investment buying takes place and hence the value of information flattens out.
Our experiments also show that the value of information slightly decreases as demand variance increases. The average value of information is 3.36% when the demand has the Erlang (7.5, 4) distribution while it is 2.86% when with demand has the Erlang (30, 1) distribution. This is because when the variability is very large, the information provided by the distributor is not enough to resolve a significant portion of the uncertainty. As the demand variance decreases, the information provided by the distributor resolves a larger percentage of the uncertainty, thus making the information relatively more valuable.
In summary, the manufacturers should ensure that they make their best efforts to incorporate the information (they receive from the distributor) into their decision making process when the inventory cap is high, price increase is large, and the end-customer demand variance is not too large. If they do not use the information, they may lose an opportunity to reduce supply-demand mismatch costs by an average of 3.63% and as much as 13.01%.
A Simple Heuristic to Estimate the Pareto-Improving Fee Range
Given that the optimal solution involves solving a multi-period model and is possibly beyond the scope of a decision maker in the real-world, in this subsection, we develop a simple heuristic that can be used to estimate the pareto-improving fee ranges given a specific inventory cap and other parameters. To develop this heuristic, we first need to understand how to obtain the upper and lower bounds of the pareto-improving fee ranges,ū and u, respectively.
Consider an N -period horizon. Based on (1) and (2), the key to estimateū and u is to estimate ∆π m and ∆π d . In the following, we develop a simple heuristic to estimate these two values.
In estimation of ∆π m , recall y d * n−1 is the optimal stock level for the distributor under IB model andȳ is the maximum stock level the distributor can reach in period n − 1 under FFS. Changing from IB to FFS, although losing profit due to less investment buying, the distributor saves on holding cost. Since the service level is quite high, we will omit the loss of penalty cost in the estimation and estimate the distributor's holding cost savings.
To do this, note that if there were no price increase, y * = Φ( increase) that cost extra holding cost for one period (period n), h dD , and there is roughlyD units sold in period n + 1 that cost extra holding cost for 2 periods (periods n − 1 and n), 2h dD , and so on. Finally, there are (k IB − k IB )D units sold in period n + k IB that cost extra holding cost,
So the estimated increased holding cost is:
Similarly, for the FFS model, let k F F S =ȳ −y * D and define k F F S to be the integer part of k F F S .
Following the same logic, we estimate the distributor's increase under FFS model compared to the no-price-increase model to be:
Then the decreased cost switching from IB to FFS model is (3) −(4). We also know the distributor's reduced revenue when switching from IB to FFS model is δ(y d * n−1 −ȳ). So the distributor's total profit loss after switching from IB to FFS model can be estimated as:
Next, we estimate the manufacturer's profit gain (∆π m ) to calculateū. When switching from IB to FFS, the manufacturer gains a revenue of δ(y d n−1 −ȳ) because of the limited investment buying. The cost should not change too much because the manufacturer basically carries enough stock for periods that he predicts that he will not see demand. So we can estimate ∆π m as δ(y d n−1 −ȳ) and the upper bound of the fee range,ū, can be estimated as
Figure 6 reflects the performance of the heuristic by showing the optimal pareto-improving fee rangesū and u and their estimates calculated from the heuristic under different inventory caps. As seen from the figure, the heuristic provides very accurate estimation of the u and a slightly (and consistently) higher estimate ofū (by about 0.3 − 0.4%). Given that the manufacturer is usually the leader in setting the per-unit fees, she is most interested in identifying u, the fee value that just motivates enough the distributor to participate in the FFS contract. Given the simplicity of the proposed heuristic and its effectiveness (almost perfect estimation of the lower fee), it can be an invaluable asset to the manufacturer in determining the per-unit fees she should offer the distributor in FFS contract negotiation. 
Conclusion
In this paper, we address some pressing questions facing the current pharmaceutical distribution industry. By comparing investment buying (IB) models and fee-for-service (FFS) models, we clarify the industry's doubts regarding which model is better, provide guidelines in how the manufacturer and the distributor operate under FFS model (a model adopted by most distributors today), and how to set the FFS contract parameters which lead to pareto improvement for both the manufacturer and the distributor. Here, we list the main managerial insights obtained from our analysis.
• We show that a transition from IB to FFS is beneficial to the supply chain as a whole and certainly is advantageous to the manufacturer. While this limits the investment buying opportunity to the distributor, an appropriate per-unit service fee can overcome this deficiency.
The improved efficiency of the supply chain under FFS ensures that there exists a range of fees that guarantee the manufacturer and the distributor achieve pareto-improvement.
• Under the FFS contract, given that the distributor is able to satisfy the service level target, as the inventory cap decreases, the manufacturer's and the supply chain's profits increase and the distributor's profit decreases.
• The values (and the range) of pareto-improving per-unit fees decrease as the inventory cap increases. Thus at lower values ofȳ, the manufacturer and the distributor have more flexibility in choosing the fees while they should be a lot more careful in setting the fees when theȳ is larger.
• Manufacturers may forego significant (on average 3.63% and as much as 13.01%) supplydemand cost savings when they do not use the distributor's inventory information that is provided to them under FFS. The value of information decreases as they impose tighter inventory cap on the distributor, when the price increase is smaller, or the end-consumer demand has a high variance.
• A simple, effective, and useful heuristic is developed that could be very useful for real-world n−1 (y * ) = 0, which implies y d * n−1 ≥ y * is the optimal stock level for period n − 1. Next consider period n − 2, we have G 
A-2. Proof for Theorem 2
Since the total production cost through the finite horizon is c
Q k , which is not dependent on the stock level, to show the property of optimal stock level we don't need to consider the production cost −c(y −x) in each period. Thus, we rewrite V i k (x) = min y≥x {G i k (y)}, where
To prove the optimality of the produce-up-to policy, we will use backward induction again. It can be easily shown that L(y), L n−1 (y) and L i (y) are convex by definition. Since we know V i N +1 (x) is convex in x for any state i, for G i N (y) whether i = 0 + or not, we know G i N (y) is convex in y by the convexity of V i N +1 . Based on the fact that if f (y) is convex then g(x) = min y≥x f (y) is also convex, we know V i N (x) = min y≥x {G i N (y)} is also convex in x for any i. Now assume in period k, G i k (y) and V i k (x) are convex for any i. We want to prove then G i k−1 (y) and V i k−1 (x) are convex for any i. Consider the situation where i = 0 − or 0 + and k = n − 1, we have G 
A-3. Proof for Corollary 1
From Theorem 2, we know for y 0 + (ȳ 1 ) = y 0 + (ȳ 2 ) = Φ −1 ( p p+h ). For the transitional periods, we know p i (ȳ 1 ) ≥ p i (ȳ 2 ) and Θ i (·|ȳ 1 ) ≥ st Θ i (·|ȳ 2 ) givenȳ 1 ≤ȳ 2 (details omitted). From Theorem 2 we know during the transitional periods, myopic policy is optimal. By using the property that Θ i (·|ȳ 1 ) ≥ st Θ i (·|ȳ 2 ), we get y i (ȳ 1 ) ≥ y i (ȳ 2 ) for i ≥ 0.
A-4. Proof for Theorem 3
If δ 1 ≤ δ 2 , we have y d * n−1 (δ 1 ) ≤ y d * n−1 (δ 2 ). We know y 0 + (δ 1 ) = y 0 + (δ 2 ) = Φ −1 ( p p+h ). For the transitional periods, we know p i (δ 1 ) ≥ p i (δ 2 ) and Ψ i (·|δ 1 ) ≥ st Ψ i (·|δ 2 ) by knowing y d * n−1 (δ 1 ) ≤ y d * n−1 (δ 2 ). In the Investment Buying model, we have similar result as Theorem 2 that during the transitional periods, the myopic policy is optimal. By using the property that Ψ i (·|δ 1 ) ≥ st Ψ i (·|δ 2 ), we get y i (δ 1 ) ≥ y i (δ 2 ) for any i ≥ 0.
